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What is already known about this topic? 
 There are no validated scoring methodologies for oral mucous membrane pemphigoid 
(MMP). Proposed disease activity scoring tools for MMP include the Mucous 
Membrane Disease Area Index (MMPDAI) and the Autoimmune Bullous Skin 
Disorder Intensity Score (ABSIS).  
 The Oral Disease Severity Score (ODSS) has been validated for use in oral 
pemphigus vulgaris (PV). It has been shown to be reliable and sensitive in both lichen 
planus (LP) and MMP. 
 
What does this study add? 
 The ODSS has been shown to be a thorough, sensitive, reproducible, yet quick 
scoring tool for the assessment of oral involvement in MMP. 
 Its versatility for use in oral PV, MMP and LP is an added advantage over other 
scoring methodologies. 
 
What are the clinical implications of this work? 
 We propose that the ODSS be used as a clinical scoring tool for monitoring disease 




Mucous membrane pemphigoid (MMP) is a rare autoimmune bullous disease predominantly 
affecting the oral mucosa. Optimal management relies upon thorough clinical assessment and 
documentation at each visit. 
 
Objectives 
The primary aim of this study was to validate the Oral Disease Severity Score (ODSS) for the 
assessment of oral involvement in MMP. We also compared its inter- and intra-observer 
reliability with the oral parts of the Mucous Membrane Pemphigoid Disease Area Index 











(MMPDAI), Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and Physician’s 




Fifteen patients with mild to moderately severe oral MMP were scored for disease severity by 
10 oral medicine clinicians from four UK centres using the ODSS, the oral sections of 
MMPDAI and ABSIS and PGA. Two clinicians re-scored all patients after two-hours. 
 
Results 
Inter-observer reliability for ODSS total score intra-class correlation coefficient (ICC) was 
0.97; MMPDAI activity 0.59 and damage 0.15; ABSIS total 0.84; and PGA 0.72. Intra-
observer ICC for ODSS total was 0.97 and 0.93; MMPDAI activity 0.93 and 0.70 and 
damage 0.93 and 0.79; ABSIS total 0.99 and 0.94; and PGA 0.92 and 0.94. Convergent 
validity between ODSS and MMPDAI was good (correlation coefficient 0.88). The 
meanSD time (seconds) for completion, ODSS 93±31 s, MMPDAI 102±24 s and ABSIS 
involvement 71±18 s. The PGA was <5 s. 
 
Conclusion 
This study has validated the ODSS for the assessment of oral MMP. It has shown superior 
inter-observer reliability than MMPDAI, ABSIS and PGA and intra-observer reliability than 
MMPDAI. It is quick and easy to perform. 
 
INTRODUCTION 
Mucous membrane pemphigoid (MMP) is a heterogeneous disease with a wide spectrum of 
clinical and immunopathological presentations. Affected sites include the oral mucosa, eye, 
skin, genitalia, larynx, oesophagus and nasopharynx.
1
 Oral manifestations of MMP include 
painful desquamative gingivitis, blistering and ulceration of the palate, buccal mucosae and 
oropharynx with occasional lesions seen on the floor of mouth, tongue and lips. There appear 
to be distinct oral phenotypes.
1
 Approximately a third of patients will experience skin lesions 
which are typically seen on the head and neck area though occasionally also affecting the 
limbs.
2
 In a small subgroup of patients it may present with a more widespread cutaneous 
blistering condition akin to bullous pemphigoid (BP), but the oral lesions are usually more 











prominent from the outset than would be expected in BP and are a clue to the diagnosis of 
MMP. The disease can have a long course and rarely remits without treatment. A wide 
variety of therapies have been used to treat MMP but there are no large placebo-controlled 
randomised controlled studies, and there are few studies utilising a standardised scoring 




As the mouth and eyes are the two most frequently involved sites in MMP, it is paramount 
that these are assessed with the most accurate, reproducible and validated methods available. 
In addition, to be valuable, a scoring tool should also be feasible, sensitive to change, and 
have external validity.
4 
To date there have been no validated scoring methodologies for any 
site in MMP.
5
 For ocular disease the most frequently used prospective scoring system is the 
Foster-Tauber tool in which the presence of subconjunctival scarring, together with 
qualitative assessments of the extent of both forniceal fore-shortening and symblepharon, are 
combined to create a four stage alpha-numeric measure of the extent of conjunctival 
scarring.
6
 However further ocular MMP scoring methodologies including assessments of the 
severity of inflammation using image based grading and quantitative measurements of 
forniceal shortening are under evaluation.
7,8,9
 In 1998 we published a multi-site scoring 
methodology for MMP. It was used to assess disease severity alongside establishing 
biomarkers for more severely affected patients.
1
 Each affected site was formally assessed by 
the relevant specialist e.g. in dermatology, oral medicine, otolaryngology or ophthalmology 
and the methodology was devised with their input. This scoring methodology was later used 
in further MMP cohort studies.
10
 However, for more accurate sequential assessment, a more 
detailed oral severity score was needed.   
 
The Oral Disease Severity Score (ODSS) was devised by the oral medicine group at Guy’s 
Hospital as part of a strategy to develop a comprehensive scoring system to record outcomes 
for oral mucosal diseases.
11
 It was developed from a multi-site methodology previously 
published for MMP.
1
 ODSS records the presence of lesions and degree of activity at multiple 
oral sites and includes a subjective assessment of the patient’s oral pain over the preceding 
week. Previous studies have demonstrated that the ODSS is a reliable and sensitive tool in 
both oral lichen planus (LP) and MMP.
11,12
 It has been recently validated for use in oral PV
13
 
and has been shown to be useful to assess therapeutic response over time in both severe 















In 2012, an International panel of experts, predominantly dermatologists, proposed a new 
scoring system, the Mucous Membrane Pemphigoid Disease Area Index (MMPDAI).
16
 This 
was adapted from the validated Pemphigus Disease Area Index (PDAI) and the Bullous 
Pemphigoid Disease Area Index (BPDAI)
17,18,19
, and is a multisite scoring methodology that 
is yet to be validated. A further tool advocated for potential use in MMP is the Autoimmune 
Bullous Skin Disorder Intensity Score (ABSIS), which has been validated for pemphigus 





The primary aim of our study was to validate the ODSS for use in MMP by investigating 
inter- and intra-observer reliability and ease of use. A secondary aim was to compare its inter- 
and intra-observer reliability and ease of use with the oral parts of the MMPDAI, ABSIS and 
the Physician’s Global Assessment (PGA).  
 
PATIENTS & METHODS 
Research ethics approval was obtained (REC15/ES/0038). The study was conducted over one 
day within the Department of Oral Medicine at Guy’s Hospital, London.  
 
Patients 
Fifteen patients (aged 31-79) with a confirmed diagnosis of predominantly oral MMP (based 
on clinical findings, histopathology and direct immunofluorescence) were recruited 
consecutively from the outpatient clinic of the Departments of Oral Medicine and 
Dermatology at Guy’s Hospital, London. The visit replaced one of their routine follow-up 
appointments. All patients had mild to moderately severe oral lesions. Fourteen patients were 
taking systemic treatment: eight sulphapyridine, two dapsone, one azathioprine, one 
mycophenolate mofetil, one prednisolone plus sulphapyridine and one prednisolone plus 




Ten clinicians experienced in diagnosing and managing patients with MMP were included 
from four oral medicine centres in the UK. All were oral medicine specialists; six were 
medically and dentally qualified, one of whom was a practicing dermatologist. Patients were 
scored using the ODSS, the oral parts of the MMPDAI and ABSIS and the PGA. All 
physicians were familiar with the PGA, five were experienced in using ODSS and five were 











not. None of the clinicians routinely used either the MMPDAI or ABSIS. Prior to the study, a 
set of training slides demonstrating the ODSS system, MMPDAI, ABSIS and PGA was sent 
to all clinicians. On the study day the chief investigator met with all the clinicians for a 
detailed discussion of methodologies using clinical slides as examples. All clinicians 
examined and scored each patient once, and two clinicians examined all patients twice with a 
two-hour interval to reduce recall. All physicians were asked for feedback regarding the 
scoring tools in relation to ease of use. An assistant recorded the scores in random order and 
the time taken for each methodology. Twelve sets of scores were recorded for each patient. 
 
Oral Disease Severity Score 
The ODSS is a comprehensive oral scoring system detailed in Figure 1 for MMP and 
previously validated for oral PV.
13
 It has been used as an outcome measure in the assessment 
of therapeutic efficacy in oral LP and PV.
11,14,15
 In the ODSS the oral cavity is divided into 17 
sites weighted 0-2 according to the area of possible involvement. These sites are the outer / 
inner lips, buccal mucosae right / left, soft palate right / left, hard palate right / left, dorsum of 
tongue right / left, ventrolateral tongue right / left, floor of mouth right / left, oropharynx right 
/ left and the gingivae (divided into 6 segments). As detailed in Figure 1, a score of 2 
corresponds to >50% of the buccal mucosa on one side being affected, or bilateral 
involvement of the dorsum of tongue, floor of mouth, hard and soft palate or oropharynx. 
Each unit of site is then allocated an activity score which ranges from 0-3 (no activity = 0, 
mild inflammation – erythema or healing areas = 1, prominent erythema = 2, and blistering or 
ulceration = 3) (Fig 2a, 2b and 2c). For a specific area e.g. buccal mucosa, the activity for 
each unit of site is added together. The third component is a pain score, which is subjective 
on a scale of 0-10 provided by the patient as an average for the preceding week. The three 
components are summed to give a total score with a theoretical maximum of 106; however 
greater than 95% of patients would be expected to have scores in the range from 0-60 
representing a clinical range from remission to severe disease. 
 
Mucous Membrane Pemphigoid Disease Area Index  
The MMPDAI was designed through consensus by a group of international experts in 
autoimmune bullous disease and is currently awaiting validation.
16
 Only the section relating 
to the oral cavity was used in our study. The oral cavity is divided into seven areas, the buccal 
mucosa, palate, upper and lower gingiva, tongue / floor of mouth, labial mucosa, and 
posterior pharynx. Scores are recorded in two columns, to separate active ulcers and blisters 











from post inflammatory changes and scarring (damage). Scores are allocated based on 
number and size of lesions with a total possible score of 70 points for mucosal activity and 7 
points for disease damage. The activity and damage scores are not added together.  
Autoimmune Bullous Skin Disorder Intensity Score  
The ABSIS scoring tool was developed by Pfutze
20
, initially for use in PV to score both skin 
and mucous membrane involvement. In our study, only the oral part of the tool was used. 
Oral involvement is scored by recording the presence or absence of lesions in 11 sites in the 
oral cavity, with each site scoring 0 or 1 and a maximum of 11. The oral cavity is divided into 
upper gingivae, lower gingivae, upper lip, lower lip, right buccal mucosa, left buccal mucosa, 
tongue, floor of mouth, hard palate, soft palate and pharynx. A subjective severity scale based 
on the patient’s assessment of discomfort during eating and drinking a range of foods is 
included with maximum score of 45. The two components are summed to provide a total 
score for oral severity. 
 
Physician Global Assessment  
The PGA is a 10-point analogue scale in which clinicians make a judgement on the overall 
health of, in this case, the oral mucosa. The scorer rates the mucosa from 0 = perfect health to 
10 = worst mucosal disease imaginable. PGA has previously been used as an outcome 
measure in dermatological conditions
21,22,23
, and has been validated for oral PV.
13
 It has not 
been validated for use in other autoimmune bullous disorders.   
 
Time for scoring methodology completion 
An independent assistant used a stopwatch to record the time taken (in seconds) by each 
clinician to obtain a disease severity score for each scoring tool except the PGA which took 
<5 seconds and was therefore not timed. ODSS time included the subjective pain 
component whereas the ABSIS timing did not include the subjective severity score. 
 
Statistical Methods 
Inter-observer reliability was assessed by 10 clinicians (observers) scoring all patients with 
each of the four scoring tools. A sample size of 15 subjects was required to achieve intra-
class correlations (ICC) of 0.77 for the inter-observer reliability. 
 
 











Intra-observer reliability was tested with two replications per subject (as per test-retest) with 
a minimum of two-hours between scores to minimise the risk of recall. Since the involvement 
was more onerous (burden, time or money resources, etc.) for the rater than for the subject, 
taking rater as fixed in the factorial design was more efficient. We fixed the number of raters 
to two and found the sample size required in terms of the number of subjects (which are 
assumed to be a random sample from the population of subjects). With both raters performing 
two replications in each methodology in all the subjects, a total of 15 subjects provided 80% 
power to detect an ICC difference of 0.50 (relative to a null value of 0.20). Anticipating an 
ICC of 0.85, 15 subjects with two replications will yield a width of 0.30 in the 95% 
confidence interval (CI). 
 
Multilevel models were used to quantify inter- and intra-observer reliabilities of the 
continuous measures. Assessment for the level of agreement in terms of the ICC for ordinal 
or continuous measures followed well-established benchmark limits (Fleiss and Altman’s 
benchmark scales).
24,25
 Landis-Koch’s benchmark values were followed when Kappa 
coefficients were used for categorical outcomes.
26
 In all cases, for more rigour, in addition to 
the point estimate, we took into account the lower bound of the 95% confidence interval.
24
 
Convergent validity was calculated using the Spearman rank correlation coefficient. 
 
RESULTS 
15 patients (f5:m10) with confirmed MMP were included. The mean±SD age was 65±11.8 
years (range 31-79).  
 
The distribution of scores:  
The mean±SD total ODSS score was 25.6±10.9, (range 6-56); median 25 with interquartile 
range [IQR] 17-32.8; reflecting mild-moderately severe disease. The mean MMPDAI activity 
score was 7.2±6.1, (range 0-31); median 6 [2-11] and mean damage was 1.6±1.4, (range 0-6); 
median 1.5 [0-3]. The mean ABSIS total score was 12.1±10.5 (range 0-36) and median 10 [2-
20]. The mean score for involvement was 3.2 ±1.5, median 3 [2-4]. For disease severity the 
mean was 9.9±9.6, median 8 [0-17.5]. The mean PGA score was 4.1±2.2, (range 1-9), median 

















The ICC (95% CI) for the ODSS total was 0.97 (0.94-0.99), ODSS site 0.73 (0.57-0.88), 
ODSS activity 0.82 (0.71-0.94) and ODSS pain 0.81 (0.68-0.93). For MMPDAI the ICC for 
activity was 0.59 (0.39-0.79) and for damage 0.15 (0.08-0.30). For ABSIS the ICC total score 
was 0.84 (0.74-0.95), for involvement 0.74 (0.59-0.89) and for patient reported severity 0.87 
(0.78-0.96). Finally, the ICC for the PGA was 0.72 (0.56-0.88) (Table 1). Table 1 also 






Intra-observer agreement between initial scoring and rescoring of the same patients 
demonstrated an ICC for ODSS total of 0.97 (0.93-1.00) and 0.93 (0.86-0.99), site 0.95 (0.90-
1.00) and 0.93 (0.85-1.00), activity 0.95 (0.90-1.00) and 0.94 (0.88-1.00) and pain 0.97 (0.94-
1.00) and 0.59 (0.25-0.93). The ICCs for MMPDAI activity were 0.93 (0.87-1.00) and 0.70 
(0.44-0.96) and damage 0.93 (0.85-1.00) and 0.79 (0.60-0.98). For ABSIS total, ICCs were 
0.99 (0.98-1.00) and 0.94 (0.89-1.00), involvement 0.98 (0.97-1.00) and 0.90 (0.79-1.00) and 
severity 0.99 (0.97-1.00) and 0.94 (0.99-1.00). The PGA ICCs were 0.92 (0.84-1.00) and 0.94 
(0.89-1.00) (Table 2). 
 
Convergent Validity  
There was good correlation between the MMPDAI activity and the ODSS total score (0.884, 
p<0.001), ODSS total with ABSIS (0.797, p<0.001) and MMPDAI activity and ABSIS 
(0.791, p<0.001) (Table 3). 
 
Time for Completion 
The mean time to obtain a disease severity score using ODSS (total) was 93±31 s, MMPDAI 
(activity and damage) 102±24 s and ABSIS (involvement) 71±18 s. 
 
DISCUSSION 
This study has shown that the ODSS is a valid scoring method for assessment of oral disease 
severity in MMP with higher inter- and intra-observer reliability than MMPDAI and higher 
inter-observer reliability than ABSIS and the PGA. The study has also validated the oral 
components of the MMPDAI and ABSIS for use in MMP. 
 











The methodologies were compared using standardised benchmark scales. The inter-observer 
score for ODSS total was classified as excellent in contrast to the MMPDAI activity score 
which was fair / moderate and the MMPDAI damage score which was poor. For ABSIS the 
total score was good / substantial and for PGA moderate / good. Thus, this study has shown 
that the ODSS was the more reliable as a scoring tool among these clinicians than MMPDAI, 
ABSIS or the PGA.  
The sample size was calculated in advance using appropriate statistical calculations in 
order to achieve an intra-class correlation of 0.77, which is considered more than 
adequate to allow assessment of reliability. As MMP is a rare disease combined with the 
requirement for all participants to attend on one day, increasing the sample size would 
have been practically difficult. 
 
We sought statistical advice on how to undertake the intra-observer methodology. By using 
two clinicians to score each patient twice, 30 scores were produced compared with 20 if each 
clinician had rescored one patient. We retested with a minimum two-hour interval to reduce 
recall bias. While a longer interval (24-48 hours) might have further reduced recall, this 
might also have been associated with subtle changes in disease activity and of practical 
relevance patients would have required two visits adding an extra burden. Although 5 out of 
the 10 investigators had experience of the ODSS, with the potential for possible bias in 
the data, there was no difference detected in the reliability of the tool between these 
groups.  For intra-observer reliability the scores for ODSS total, ABSIS total and PGA were 
classified as excellent. For MMPDAI activity and damage, benchmark ratings were good / 
substantial. Thus, the ODSS had similar or better intra-observer scores than the other scoring 
tools examined.  
 
Accuracy of any scoring system is best assessed against a gold standard. However, for MMP 
no gold standard exists, as there are no validated scoring methods with which to compare.  
There was good convergent validity between the oral part of MMPDAI activity and ODSS 
total, ODSS total and ABSIS as well as MMPDAI and ABSIS. The validity of a tool also 
depends on how well the variables in the study represent the phenomenon of interest 
(construct validity). Whilst construct validity was not the aim of this study nor addressed 
formally, the variables in the ODSS contain objective measures of disease activity and 
severity as well as including patient subjective data allowing for a comprehensive 
appraisal of mucosal disease. 
11
 Construct validity may be an area for further 











investigation in the future. These outcome measures were identified as important by the 




 The scores can be reported separately giving an 
accurate assessment by both clinician and a patient reported outcome. It should be noted 
that although ODSS contains a subjective element it does not replace a quality of life 
measure. The granularity of the ODSS scoring system allows this component to be 
assessed separately from the other aspects of disease severity. In order to capture 
patient experience ODSS, MMPDAI and ABSIS can be combined with patient reported 
outcome measures. The ODSS has been externally evaluated for use in MMP
10 
and validated 




In terms of the practical use of these methodologies in the clinical setting, the average time 
taken to complete each of the scoring tools was less than two minutes (ODSS 93 s, MMPDAI 
116 s and ABSIS 71 s), which we consider feasible for use on routine clinics. The PGA 
typically takes <5 seconds and was therefore not timed. Since there was no significant 
difference in the time taken for those familiar with ODSS and other clinicians, we extrapolate 
that these mean differences reflect ease of use. However, all were felt to be practical for use 
in the clinical setting.  
 
Clinicians were asked to comment on their experience of using each scoring tool. They 
reported that the ODSS was easy to use and most accurately recorded the extent of oral 
disease in MMP, recording more detailed activity across more sites, thereby having a wider 
scale. ABSIS was the easiest tool to assess activity recording blisters or ulcers at only 11 
sites. However, there was loss in sensitivity as erythema was not included although present in 
pre-blistering lesions or stable inflammation. The substantial subjective component of ABSIS 
requires the patient to report symptoms with food types and the results showed differing 
answers depending upon how the questions were put to the patient. Clinicians felt the ABSIS 
scoring system was weighted too strongly on this subjective component. The PGA, while 
simple and very quick, was felt to offer little information regarding the objective oral 
involvement of MMP so its potential for sequential monitoring of disease was limited. 
 
The MMPDAI is the only scoring tool to include an activity and damage component. 
For the mouth, it requires lesions to be an ulcer or a blister to be active while scarring, 
erythema and post-inflammatory changes are descriptors for damage. Inclusion of a 
damage score for multisite MMP is valuable albeit that scarring is an unusual finding in 











the oral mucosa. However, the omission of erythema as a descriptor for activity 
precludes those lesions that are stable but erythematous and therefore in the oral mucosa, 
inflamed. The authors of the MMPDAI have subsequently acknowledged that the term 
‘active erythema’ was missing as a descriptor for the proof of the 2015 paper and an 
erratum has been submitted. In contrast to PV, gingival erythema in MMP may last months 
or years, is usually symptomatic, requires active monitoring and often systemic therapy. 
Thus, oral physicians unanimously felt this should more correctly represent activity rather 
than damage and may in part have accounted for the longer time taken to complete the 
scoring. Clinicians also reported difficulty in assessing the level of activity where there was 
localised or patchy gingival ulceration, finding the 10-point scale more difficult to adapt to 
the gingiva.  
 
While the MMPDAI is intended for use by dermatologists in ‘mild MMP’ but not in patients 
with severe ocular or laryngeal disease, patients with oral lesions occur in both groups. 
Furthermore, those with mild disease will present to a range of specialists and therefore a 
scoring methodology that is applicable to all patients and all clinicians is arguably more 
useful. As neither oral physicians nor dermatologists are skilled in ocular assessment, and 
disease progression does not always manifest as erythema, a total score that includes oral and 
ocular specific methods but with additional sites assessed would be optimal. 
 
An ideal scoring system should be able to assess a patient’s baseline severity to aid 
assessment, monitor progress longitudinally throughout treatment and detect relapse.
4
 The 
ODSS has been used in this way in our department for over 10 years for oral MMP, PV and 
LP. It has been shown to be valuable tool in longitudinal studies in oral LP and PV
14,15
 and 
has revealed distinct clinical phenotypes in MMP, which appear to be stable over long 
periods of time. 
 
This study has demonstrated the value of the ODSS for assessment of disease severity in 
MMP and by assessing activity at 17 oral sites it provides the potential to accurately 
monitor response to treatment. It is easy to use and quick to learn and is designed for use in 
oral medicine, dermatology and other relevant clinical specialities. Its additional versatility 
for use in PV and LP is an added advantage over other scoring methodologies. We propose 
that this scoring tool would be useful for recording sequential disease activity routinely in 
the clinic as well as in future multicentre studies. 
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Table 1. Scores and inter-observer reliability for each of the disease severity scoring systems, 
and their individual components 
 
ODSS, Oral Disease Severity Score; MMPDAI, Mucous Membrane Pemphigoid Disease 
Activity Index; ABSIS, Autoimmune Bullous Skin Disorder Intensity Score; PGA, 
Physician’s Global Assessment; SD, standard deviation; IQR, interquartile range; ICC, intra-
class correlation coefficient; CI, confidence interval 
 
*Assessment for the level of agreement in terms of the intra-class correlation coefficients 















Moderate / Good 





































Moderate / Good 


































Table 2. Within observer (intra-observer) reliability data for each scoring methodology 
 
ODSS, Oral Disease Severity Score; MMPDAI, Mucous Membrane Pemphigoid Disease 
Area Index; ABSIS, Autoimmune Bullous Skin Disorder Intensity Score; PGA, Physician’s 
Global Assessment; SD, standard deviation; IQR, interquartile range; ICC, intra-class 
correlation coefficient; CI, confidence interval 
 
*Assessment for the level of agreement in terms of the intra-class correlation coefficients 




Scoring system Observer 1 ICC  
(95% CI) 
Observer 2 ICC 
(95% CI) 
P-value Overall benchmark values* 














0.35 Moderate / Good 
















0.28 Good / Substantial 





































Table 3. Convergent validity of disease severity scoring systems  
 
ODSS, Oral Disease Severity Score; MMPDAI, Mucous Membrane Pemphigoid Disease 
Area Index; ABSIS, Autoimmune Bullous Skin Disorder Intensity Score 
 
Scoring system Correlation coeffficient P-value 
ODSS total & 
MMPDAI activity 
0.884 <0.0001 
ODSS total & 
ABSIS total 
0.797 <0.001 





Figure 1.  
Oral Disease Severity Score (ODSS)    
Figure 2a.  
Upper central gingivae indicating mild erythema (site score = 1, activity 1)  
Figure 2b.  
Upper central gingivae indicating marked erythema (site score = 1, activity = 2)  
Figure 2c.  
Hard palate demonstrating areas of ulceration bilaterally (site score = 2, activity = 3+3 = 6)  
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